Cited by 35TGF-β signaling in diseasesBreast Cancer Treatment StudiesMechanisms of cancer metastasis

The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.

Differential expression of TGFβ isoforms in breast cancer highlights different roles during breast cancer progression

Open access

Abstract

While TGFβ plays a critical role in tumor formation and progression, the role and contribution of its three different isoforms remain unclear. In this study, we aimed at elucidating the prognostic value of the TGFβ isoforms and assessed their expression levels in breast cancer patients at different stages of the disease. We found higher levels of TGFβ1 and TGFβ3 in cancer patients compared to normal tissues, with no significant changes in TGFβ2 expression. Similarly, TGFβ1 and TGFβ3, but not TGFβ2, showed higher expression levels in advanced lymph node–positive and metastatic tumors, suggesting different roles for the different isoforms in tumor progression and the metastatic process, while in the least aggressive molecular subtype (luminal A), expression of the three TGFβ isoforms significantly correlated with expression of both TGFβ receptors, such correlation only occurred between TGFβ1 and TGFβ3 and the TGFβ type II receptor (TβRII) in the highly aggressive basal-like subtype. Interestingly, a distinct and somehow opposite pattern was observed in HER-2 tumors, only showing significant association pattern between TGFβ2 and the TGFβ type I receptor (TβRI). Finally, the three TGFβ isoforms showed distinct association patterns with patient outcome depending on the different molecular subtype, highlighting context-dependent, differential prognostic values.

Overview

Integrity signals

Registry

Crossref · 10.1177/1010428317748254

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 38 references

Research works printed but not linked: 4

  1. Lebrun JJ., 2012, ISRN Mol Biol, 2012
  2. Humbert L, 2010, Trends in Cell Mol Biol, 5, 69
  3. Dai X, 2015, Am J Cancer Res, 5, 2929
  4. Burrows FJ, 1995, Clin Cancer Res, 1, 1623

Cited by

Sorted by citations

See all 35

Metadata

Authors
Hachim, M. Y., Hachim, I. Y., Dai, M., Ali, S., & Lebrun, J.-J.
Affiliations
McGill University Health Centre (CA)
Corresponding author
Lebrun, Jean-Jacques
Venue
Tumor Biology
Published
2018-01
Volume
40
Issue
1
Pages
101042831774825
ISSN
  • 1010-4283 (ISSN-L)
  • 1423-0380
OpenAlex
W2783563529
Cited by
35
References
38
Citations by year
2025: 2 · 2024: 4 · 2023: 3 · 2022: 6 · 2021: 7 · 2020: 10 · 2019: 1 · 2018: 2
FWCI
1.78
Type
journal article
Language
en
Open access
Locations
  • Tumor Biology (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mechanisms of cancer metastasis
Keywords
breast cancer, TGF-β1, TGF-beta2, TGF-beta3, tumor progression, metastasis, lymph node metastasis, TGF-beta receptor, breast cancer molecular subtypes, luminal A, basal-like subtype, HER2-positive breast cancer, prognostic factors, patient outcomes
MeSH terms
Breast Neoplasms, Female, Humans, Immunohistochemistry, Middle Aged, RNA, Messenger, Receptors, Transforming Growth Factor beta, Disease Progression, Spheroids, Cellular, Gene Expression Profiling, Cell Line, Tumor, Transforming Growth Factor beta1, Transforming Growth Factor beta2, Transforming Growth Factor beta3

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review